ABSTRACT Background This study assessed the pharmacokinetics (PK), pharmacodynamics (PD) and safety of QHRD106, and made a comparison with urinary kallindinogenase (UKN) in healthy volunteers. Methods This study comprised a randomized, double-blind, placebo-controlled, single-dose escalation phase and an open-label, multiple-dose escalation phase. 94 subjects received intramuscular injections of QHRD106/placebo only once and 30 subjects received QHRD106 four times. 6 subjects received 0.15 PNA units UKN intravenously for 7 d. PK and PD analysis were conducted by using a electrochemiluminescent assay and a liquid chromatography/mass spectrometry methodology respectively. Cerebral circulation was assessed by the magnetic resonance imaging system. Results QHRD106 exhibited a slow absorption profile in the human body. Compared to UKN, QHRD106 induced changes in bradykinin concentration later, but with a noticeably prolonged duration. Compared to baseline, cerebral blood flow exhibited a significant improvement on d 7 after a single dose of 18,900 IU and an improvement from d 2 to d 14 after multiple dose of 8400 IU of QHRD106. QHRD106 appeared generally good safety and no severe adverse events occurred in all the groups. Conclusions This study provided initial evidence of potential treatment for ischemic strokes that the QHRD106 injection functioned as a safe and effective long-acting kallikrein drug. Registration This study was registered on ClinicalTrials.gov with the identifier NCT06380699 and NCT06388772.
Read full abstract